title: Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous ThromboEmbolism Registry (SWIVTER).
abstract: BACKGROUND
  Venous thromboembolism (VTE) prophylaxis remains underutilized, particularly in cancer patients. We explored clinical predictors of prophylaxis in hospitalized cancer patients before the onset of acute VTE.
  
  
  METHODS
  In the SWiss Venous ThromboEmbolism Registry, 257 cancer patients (61 +/- 15 years) with acute VTE and prior hospitalization for acute medical illness or surgery within 30 days (91% were at high risk with Geneva VTE risk score > or =3) were enrolled.
  
  
  RESULTS
  Overall, 153 (60%) patients received prophylaxis (49% pharmacological and 21% mechanical) before the onset of acute VTE. Outpatient status at the time of VTE diagnosis [odds ratio (OR) 0.31, 95% confidence interval (CI) 0.18-0.53], ongoing chemotherapy (OR 0.51, 95% CI 0.31-0.85), and recent chemotherapy (OR 0.53, 95% CI 0.32-0.88) were univariately associated with the absence of VTE prophylaxis. In multivariate analysis, intensive care unit admission within 30 days (OR 7.02, 95% CI 2.38-20.64), prior deep vein thrombosis (OR 3.48, 95% CI 2.14-5.64), surgery within 30 days (OR 2.43, 95% CI 1.19-4.99), bed rest >3 days (OR 2.02, 95% CI 1.08-3.78), and outpatient status (OR 0.38, 95% CI 0.19-0.76) remained the only independent predictors of thromboprophylaxis.
  
  
  CONCLUSIONS
  Although most hospitalized cancer patients were at high risk, 40% did not receive any prophylaxis before the onset of acute VTE. There is a need to improve thromboprophylaxis in cancer patients, particularly in the presence of recent or ongoing chemotherapy.
authors.affiliation: Department of Cardiovascular Medicine, University Hospital Zurich, Zurich. kuchernils@yahoo.com
authors.forename: N
authors.initials: N
authors.lastname: Kucher
authors.forename: D
authors.initials: D
authors.lastname: Spirk
authors.forename: I
authors.initials: I
authors.lastname: Baumgartner
authors.forename: L
authors.initials: L
authors.lastname: Mazzolai
authors.forename: W
authors.initials: W
authors.lastname: Korte
authors.forename: D
authors.initials: D
authors.lastname: Nobel
authors.forename: M
authors.initials: M
authors.lastname: Banyai
authors.forename: H
authors.initials: H
authors.lastname: Bounameaux
mesh_terms: D000208:Acute Disease; D000925:Anticoagulants / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D005260:Female; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011292:Premedication / Q000706:statistics & numerical data*; D011379:Prognosis; D012042:Registries; D054556:Venous Thromboembolism / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D000970:Antineoplastic Agents